Refer to…
Efficacy and safety of topical sofpironium bromide gel for the treatment of axillary hyperhidrosis: A phase II, randomized, controlled, double-blinded trialBrandon Kirsch et al. J Am Acad Dermatol. 2020 Jun.
Results: At the end of therapy, 70%, 79%, 76%, and 54% of participants in the 5%, 10%, 15%, and vehicle groups exhibited ≥1-point improvement in HDSM-Ax (P < .05).
Assuming the pulled release is accurate. They may have decided to approve a midpoint (chose 12.45%) between 10-15% considering 10% elicited the slightly better results v 15% (79-76%).
note: Approval in Japan is for 5% sofpironium bromide gel.
So no problem at all.
- Forums
- ASX - By Stock
- Ann: Trading Halt
Refer to…Efficacy and safety of topical sofpironium bromide gel...
-
- There are more pages in this discussion • 50 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BOT (ASX) to my watchlist
|
|||||
Last
31.5¢ |
Change
-0.030(8.70%) |
Mkt cap ! $570.1M |
Open | High | Low | Value | Volume |
34.5¢ | 34.5¢ | 31.5¢ | $6.354M | 19.19M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
13 | 286322 | 31.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
32.0¢ | 28500 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
11 | 180009 | 0.315 |
18 | 612167 | 0.310 |
25 | 707775 | 0.305 |
48 | 1182708 | 0.300 |
7 | 285599 | 0.295 |
Price($) | Vol. | No. |
---|---|---|
0.320 | 28500 | 1 |
0.325 | 165000 | 4 |
0.330 | 288879 | 4 |
0.335 | 197222 | 4 |
0.340 | 394838 | 8 |
Last trade - 16.10pm 01/07/2024 (20 minute delay) ? |
Featured News
BOT (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online